We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Executive summary of quality assurance (QA) visit to North West London held on 26 September 2017.
Distances between locks on the River Thames and measurements restricting navigation.
These Directions came into force on 1 September 2011.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Tower Hamlets CCG area.
Guidance on the risk assessment, investigation and management of infection control breaches, particularly concerning bloodborne virus (BBV) transmission.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Thanet CCG area.
Executive summary of the abdominal aortic aneurysm (AAA) quality assurance (QA) visit to Thames Valley held on 3 October 2019.
Executive summary of quality assurance (QA) visit to North London held on 28 February 2019.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Lambeth CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Erewash CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Basildon and Brentwood CCG area.
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.
The MHRA is reviewing the evidence relating to the very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with medicines containing pseudoephedrine
Government removes ban on UK-sourced blood plasma for the manufacture of immunoglobulins.
We want to remind healthcare professionals that use of systemic (oral and injectable) NSAIDs such as ibuprofen, naproxen, and diclofenac is contraindicated in the last trimester of pregnancy (after 28 weeks of pregnancy).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).